Moderna, a Boston–based Bio–tech company announced on Monday 18 May 2020, that initial trial data has shown positive results.

Moderna’s mRNA-1273 vaccine, which was the first US company to put vaccine into Human trails as early as April is completing Phase ll trails and may be in a position to start a large Phase lll trials as early as July.

The data on 45 participants in the early stage, showed that those on a lowest doses showed the same level of antibodies as seen in recovered COVID-19 patients. The group on the increased dosage showed higher level of antibodies. Stéphane Bancel, Moderna’s CEO, explained to the Financial Times. “What is really special about mRNA technology is we have pushed it to a place where more antibodies are made than a natural infection so it should provide long term immunity.”

Mr Bancel added that , “ …even if the vaccine showed an efficacy rate as low as 60 or 70 per cent, it could be useful in stopping the replication rate of the virus.”